Last updated on September 2018

A 24-Month Study to Evaluate the Efficacy and Safety of E2609 in Subjects With Early Alzheimer's Disease_


Brief description of study

The name of this trial is MissionAD2. This 24-month treatment, multicenter, double-blind, placebo-controlled, parallel group, Phase 3 study in participants with Early Alzheimer's Disease (EAD) including mild cognitive impairment (MCI) due to Alzheimer's Disease (AD)/Prodromal AD and the early stages of mild AD will be conducted to evaluate the efficacy and safety of elenbecestat (proposed international nonproprietary name [pINN]) (E2609).

Clinical Study Identifier: NCT03036280

Contact Investigators or Research Sites near you

Start Over

Eisai Medical Information

Eisai Trial Site 1
Katsushika-ku, Japan
  Connect »

Eisai Medical Information

Eisai Trial Site 4
Bunkyo-ku, Japan
5.05miles
  Connect »

Eisai Medical Information

Eisai Trial Site 1
Koto-ku, Japan
5.56miles
  Connect »

Eisai Medical Information

Eisai Trial Site 1
Bunkyo-ku, Japan
5.87miles
  Connect »

Eisai Medical Information

Eisai Trial Site 2
Bunkyo-ku, Japan
5.87miles
  Connect »

Eisai Medical Information

Eisai Trial Site 3
Bunkyo-ku, Japan
5.87miles
  Connect »

Eisai Medical Information

Eisai Trial Site 1
Chuo-ku, Japan
6.58miles
  Connect »

Eisai Medical Information

Eisai Trial Site 1
Urayasu, Japan
6.96miles
  Connect »

Eisai Medical Information

Eisai Trial Site 1
Minato-ku, Japan
7.98miles
  Connect »

Eisai Medical Information

Eisai Trial Site 1
Kawaguchi, Japan
8.2miles
  Connect »

Eisai Medical Information

Eisai Trial Site 1
Shinjuku-ku, Japan
8.76miles
  Connect »

Eisai Medical Information

Eisai Trial Site 2
Shinjuku-ku, Japan
8.76miles
  Connect »

Eisai Medical Information

Eisai Trial Site 1
Shibuya-ku, Japan
9.76miles
  Connect »